NCT05256810TERMINATEDanonymous

A Phase 1/2, Randomized, Double-blind, Placebo-controlled, Single Ascending and Multiple Dose Study of the Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of ALN-XDH in Healthy Adult Subjects and Adult Patients With Gout

Sponsor

Source record

Alnylam Pharmaceuticals

Phase

Source record

PHASE1

Modality

AI-normalized

small molecule

Target

AI-normalized

ALN-XDH, Placebo

Indication / condition

AI-normalized

Gout

Intervention

Source record

ALN-XDH, Placebo

Source & freshness

Source record

NCT ID

NCT05256810

Original source

ClinicalTrials.gov

Source last updated

Mar 29, 2024

Ingested at

Jun 11, 2026

Internal sync

Jun 11, 2026

Model version

trialsignal-ai-v1

Normalized confidence

96%

Validation status

validated

Open original registry record

View original source fields

NCT ID

NCT05256810

Title

A Phase 1/2, Randomized, Double-blind, Placebo-controlled, Single Ascending and Multiple Dose Study of the Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of ALN-XDH in Healthy Adult Subjects and Adult Patients With Gout

Sponsor

Alnylam Pharmaceuticals

Status

TERMINATED

Phase

PHASE1

Condition raw

Gout

Condition normalized

Gout

Modality raw

small molecule

Modality normalized

small molecule

Target raw

ALN-XDH, Placebo

Target normalized

ALN-XDH, Placebo

Interventions

ALN-XDH, Placebo

Public preview

Source record

The purpose of this study is to:

Part A: Evaluate the safety and tolerability of single ascending doses of ALN-XDH in healthy adult participants

Part B: Evaluate the safety, tolerability and efficacy of ALN-XDH as monotherapy in adult patients with gout

Part C: Evaluate the safety, tolerability and efficacy of ALN-XDH as add-on therapy in adult patients with gout

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections

Patent/IP landscape with verified records when available

Board-ready PDF export with source provenance

Save to folders and synthesize multiple assets in premium workspace

Create account

Create a free account first, then unlock a single report, buy credits or subscribe.

Investment-Ready Snapshot

The purpose of this study is to: * Part A: Evaluate the safety and tolerability of single ascending doses of ALN-XDH in healthy adult participants * Part B: Evaluate the safety, tolerability and efficacy of ALN-XDH as monotherapy in adult patients with gout * Part C: Evaluate the safety, tolerability and efficacy of ALN-XDH as add-on therapy in adult patients with gout

A Phase 1/2, Randomized, Double-blind, Placebo-controlled, Single Ascending and Multiple Dose Study of the Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of ALN-XDH in Healthy Adult Subjects and Adult Patients With Gout

Source & freshness

Public preview

Create an account to unlock this report

A Phase 1/2, Randomized, Double-blind, Placebo-controlled, Single Ascending and Multiple Dose Study of the Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of ALN-XDH in Healthy Adult Subjects and Adult Patients With Gout

Investment-Ready Snapshot

Provenance

Protocol Description

Outcome Measures

Eligibility

Known Results And Readout Context

Patent And IP Landscape

Contacts